Phenotypic screening of human iPSC-derived neurons identifies thienopyridones as neuritogenic small molecules

Read full text Summarise with VIRAT
Authors: Keiko Imamura, Hiroshi Yukikate, Takeshi Hioki, Aya Okusa, Keisuke Shibata, Iñigo Narvaiza, Akira Kaieda, Bunnai Saito, Nozomu Sakai, Dang Ngoc Anh Suong, Takeshi Niki, Yuko Arioka
+2 more Norio Ozaki, Haruhisa Inoue
Cited by: 0
References: 33

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Human induced pluripotent stem cell (iPSC)-derived neurons provide a platform for modeling brain disorders. Among disease-relevant cellular phenotypes, impaired neurite outgrowth has emerged as an indicator reflecting key aspects of neurological disease pathophysiology. We conducted a high-throughput phenotypic screening of over 21,000 small molecules to identify compounds that enhance neurite outgrowth in iPSC-derived neurons, and we identified three bioactive compounds sharing a common indazole scaffold. Notably, one of these compounds selectively targets TNIK, a kinase involved in neuronal development. Scaffold expansion led to the discovery of thienopyridone derivatives with potent neurite-promoting activity. Two thienopyridone compounds were further validated in a human neural organoid model, in which their neurite outgrowth-promoting effects were reproducibly confirmed. Transcriptomic profiling revealed activation of signaling pathways associated with neurotrophic stimulation. These findings identify thienopyridones as a scaffold for neuritogenic small molecules, suggesting their potential as a therapeutic strategy for brain disorders and for promoting neural regeneration.

Fields of Study & Subjects

Pluripotent Stem Cells Research Neurogenesis and neuroplasticity mechanisms Nerve injury and regeneration

Publication details

Journal / source
iScience
Volume
29
Issue
5
Pages
115529–115529
Publication date
31 March 2026
Language
EN